✦ LIBER ✦

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

✍ Scribed by Graux, Carlos; Sonet, Anne; Maertens, Johan; Duyster, Justus; Greiner, Jochen; Chalandon, Yves; Martinelli, Giovanni; Hess, Dagmar; Heim, Dominik; Giles, Francis J.; Kelly, Kevin R.; Gianella-Borradori, Athos; Longerey, Blandine; Asatiani, Ekaterine; Rejeb, Narmyn; Ottmann, Oliver G.

Book ID: 123544284
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 526 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.04.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase l study of three different dosin

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

✍ M. Mita, M. Gordon, N. Rejeb, A. Gianella-Borradori, V. Jego, A. Mita… 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 330 KB

A phase I schedule dependency study of t

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

✍ Raymond, E.; Alexandre, J.; Faivre, S.; Goldwasser, F.; Besse-Hammer, T.; Gianel 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 270 KB

Investigational Aurora A kinase inhibito

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

✍ Falchook, Gerald; Kurzrock, Razelle; Gouw, Launce; Hong, David; McGregor, Kimber 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 856 KB

Phase I dose escalation study of MK-0457

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

✍ Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Stev 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 252 KB

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase I, open-label, multicentre, dose-e

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

✍ Patrick Schöffski; Suzanne F. Jones; Herlinde Dumez; Jeffrey R. Infante; Elke Va 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 215 KB